ImetelChat

We are all waiting for the formal approval of Imetelstat. As far as I can tell from John Scarlett's comments, everything is on track and ready to go. ODAC recommends (12 YES votes from blood cancer experts, 2 No votes) and the FDA approves. I don't believe that there has ever been any deviation from...

As investors, now is the time to focus on the PPS. The uniqueness of Rytelo (imetelstat) as a treatment for blood cancers (starting with transfusion independence) is just beginning to be understood as very beneficial now (by itself) and as a treatment, building component, research tool, and in some...

FOSTER CITY, Calif.--(BUSINESS WIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: Stifel’s 2024 Virtua...

I believe we can finally concentrate on the PPS. ODAC has spoken and the FDA always accepts their positive, overwhelmingly good recommendations (12 yes including blood cancer experts, 2 no ). I believe we are close to $4 PPS, and moving higher. Off-label uses will come into focus. =================...

There is no medicine that does what Rytelo (imetelstat) can do as a stand alone medicine (transfusion independence, improved quality of life, longer life, disease modification, remissions, etc.). On approval (now a formality) off label uses will be suggested and tested. High on the list will be chem...

In the case of ODAC (Oncology Drug Advisory Committee) when they recommend positively and overwhelmingly (12 Yes to 2) the FDA has NEVER rejected their expert advise. I know of no blood cancer oncologist that has spoken against RYTELO (Imetelstat). Many have spoken publicly on its behalf. NOTE: Of ...

MIAMI, FLORIDA (March 14, 2024) – Dr. Mikkael Sekeres is an expert in blood cancers at Sylvester Comprehensive Cancer Center - University of Miami Health System. He served on the Oncologic Drugs Advisory Committee (ODAC) for the trial that led to imetelstat vote of support at the FDA today. Imetels...

We know exactly what will happen. ODAC has recommended Imetelstat (March 14th) and the FDA always accepts overwhelmingly positive votes (12 YES votes from blood cancer oncologists, 2 NO votes from others). This is not controversial. Imetelstat kills cancer stem-cells in 2 ways and is needed now by ...

The Chair (Ravi) was not up to speed on the importance of Imetelstat to the blood cancer world as a vital 'tool' in transfusion control and well beyond (quality of life, increased survival time, disease modification, combinations, hemoglobin increases ). I suspect he is there by now. ==============...

Turn off the SUN. It causes cancer. The alternatives are difficult to find. Many things cause cancer if you get too much. What is a safe level? (benefit vs. risk again) New, more sensitive sensors are always being invented.

Imetelstat is a breakthrough blood cancer medicine that works for many today, and has almost unlimited potential (kills cancer stem-cells in two ways) in combinations going forward. The 12 YES, 2 NO votes was 100% favored by the ODAC oncology hematologists. “ While  a  significant  minority  of  pa...

The benefits of Imetelstat out weigh the risks (not even close) All of the important negatives are temporary and reversible for both responders and non-responders. Obviously, more research is required (partners are a consideration), but that is not a reason to deny it to those who can benefit today...

The Die is Cast Certainly, JS knows more than he is telling us about partners and buyouts. There seems to be a 'Geron-factor' (some would say, a 'Geron-curse') with a level of uncertainty that is holding the PPS at these levels. CKTC found 2 cases (ODAC recommended, FDA rejected). If possible (curi...

It very unlikely that the FDA would reject their ODAC's recommendation for approving Imetelstat. Still we are a bit nervous about the FDAs "devil's advocates" comments (March 14) and the (NO) vote of the chairperson. The FDA has much on its table these days, as their past and future is now being re...

I will refer to him as Dr. Smith. To me, the subject of interest is the "litigation economics" and the fact that Sergei (Dr. Sergei Gryaznov, now at MAIA)) spent so much time with both companies developing Imetelstat and THIO as important cancer medicines. Which patents, with his name belong to Ger...

jay --- Most men that I know with PhDs, that do not have medical degrees, prefer to be called (Mr.) . The interesting thing about Mr. Smith, is that his background is litigation economics. Assuming that the FDA does not create some last-minute difficulty with the NDA approval and takes ODAC's posit...

News about Dr. Stan Smith (Will patent considerations bring Geron and MAIA together in some form of collaboration?) ============ MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement March 22, 2024 3:00 PM EDT Tweet Share E-mail Dr. Smith has pa...

Some History for those that are new to this board ======================== Posted Dec. 27, 2023 Telomerase Inhibitors for Potentially 90% of all Cancers MD Anderson and the University of Texas medical unit are already partners. They are building the ulitmate cancer research and treatment center in ...

I am sure Sergei is very happy. MAIA is getting a very strong tail-wind from Imetelstat's very positive ODAC recommendation. Some have previously suggested that there are overlapping patents. It would make both good business sense and good medical sense for both companies (Geron and MAIA) to find a...